Coloplast Affirms FY2026 Sales Guidance of $4.499B vs $4.420B Est
Coloplast (OTC:CLPBY) affirms FY2026 sales outlook from $4.499 billion to $4.499 billion vs $4.420 billion estimate.
Read original at benzingaStocks · News reference
Full Transcript: Coloplast Q3 2026 Earnings Call
Coloplast (OTC:CLPBY) released third-quarter financial results and hosted an earnings call on Tuesday. Read the complete transcript below. Benzinga APIs provide real-time access to earnings call transcripts and
Reference details
Connected markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Aug 18, 2026, 10:17 AM
- Checked
- Aug 18, 2026, 10:17 AM
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related headlines
Coloplast Q3 Adj. EPS $0.10, Inline, Sales $1.144B Beat $1.120B Estimate
Coloplast (OTC:CLPBY) reported quarterly earnings of $0.10 per share which met the analyst consensus estimate. This is a 66.67 percent increase over earnings of $0.06 per share from the same period last year. The
Read original at benzingaColoplast’s Next Generation Inflatable Penile Prosthesis Approved by the FDA – can help millions of men
Coloplast announced FDA approval of Titan Prime, its next-generation inflatable penile prosthesis (IPP) designed to treat severe erectile dysfunction affecting approximately 30 million men in the US. The device features proprietary Bioflex polymer technology offering greater strength and durability than silicone competitors, with improved comfort and concealability. Titan Prime will be available in the U.S. starting in late 2026 through a phased launch.
Read original at globenewswire-inc